Company news

Enanta Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference

May 28, 2024

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference

May 6, 2024

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4: 30 p.m. ET

May 5, 2024

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

April 29, 2024

Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 29, 2024

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4: 30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024

April 28, 2024

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

April 16, 2024

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

March 5, 2024

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4: 30 p.m. ET

February 6, 2024

Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

February 5, 2024

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4: 30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023

January 30, 2024

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

January 3, 2024

Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference

November 21, 2023

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4: 30 p.m. ET

November 19, 2023

Enanta Pharmaceuticals to Host Conference Call on November 20 at 4: 30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023

November 12, 2023

Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline

October 12, 2023

Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference

September 16, 2023

Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023

September 6, 2023

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4: 30 p.m. ET

August 6, 2023

Enanta Pharmaceuticals to Host Conference Call on August 7 at 4: 30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023

July 30, 2023

Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

June 19, 2023

Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023

June 6, 2023

Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference

May 30, 2023

Enanta Pharmaceuticals to Participate in Two Investor Conferences in May

May 8, 2023

Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19

May 7, 2023

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4: 30 p.m. ET

May 7, 2023

Enanta Pharmaceuticals to Host Conference Call on May 8 at 4: 30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023

May 1, 2023

Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million

April 24, 2023

Enanta Pharmaceuticals Presents Data for its COVID-19 and Respiratory Syncytial Virus Programs at the 33rd European Congress of Clinical Microbiology and Infectious Diseases

April 16, 2023

Enanta Pharmaceuticals Receives FDA Fast Track Designation for EDP-323, its Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

April 5, 2023

Enanta Pharmaceuticals to Present Data at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

April 4, 2023

Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research

March 13, 2023

Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 6, 2023

Enanta Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference

February 6, 2023

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4: 30 p.m. ET

February 6, 2023

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4: 30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022

January 30, 2023

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference

January 5, 2023

Enanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Enanta Pharmaceuticals to Participate in Two Investor Conferences in November

November 21, 2022

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4: 30 p.m. ET

November 20, 2022

Enanta Pharmaceuticals to Host Conference Call on November 21 at 4: 30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022

November 13, 2022

Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

November 8, 2022

Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022

October 18, 2022

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus

October 16, 2022

Enanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus

October 2, 2022

Enanta Pharmaceuticals Presents Preclinical Data for its Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Programs at the 12th International RSV Symposium

September 28, 2022

Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium

September 21, 2022

New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022

September 6, 2022

Enanta Pharmaceuticals to Participate in Two Investor Conferences in September

August 31, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 15 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.